


NUVISAN



DRUG DISCOVERY

Integrated Degradator Platform

www.nuvisan.com

INTEGRATED DEGRADER PLATFORM



DEGRADER LIBRARY WITH

>20 Ligands for E3 ligases
>7000 Linkers
>100 Precursors

END TO END DEGRADER PACKAGES

From Chemistry
to Biological
Insights



**>50 Scientists &
Lab Professionals**

Long-standing Degraders
(PROTACs and Molecular Glues)
Experience / Cross-functional
Integrated Drug Discovery



Direct-to-Biology (D2B)


Approach (100+ Degraders/Day)



3 MIO

COMPOUND LIBRARY

with 1 Billion
in vitro/in vivo data points
(HTS, Virtual Screening
& Data mining)



Availability of all assay
formats for biochemical and
cell-based assays for effective
degrader screening flow



STATE-OF-THE-ART

in vitro and *in vivo* Models
(AAALAC accredited)

Our Integrated Degradation Platform

With decades of expertise in the field of biological research and drug discovery, NUVISAN provides a fully integrated protein degradation platform encompassing a full range of PROTAC/Molecular Glue drug discovery services, utilizing cutting-edge technologies. Our services span both chemistry and biology to align with your novel drug discovery goals. We offer packages that include a variety of tailored services covering the entire drug discovery process.

- We offer integrated solutions to take your degrader molecule **from target validation to investigational new drug (IND)**
- Our design and highly efficient synthesis platform, combined with high-quality *in vitro* assays, offers a quick turnaround time, enabling informed decisions to advance your degrader discovery program
- We offer >100 diverse *in vivo* models across various therapeutic areas, such as oncology, inflammation, CNS disorders, dermatology, metabolic diseases, and female health, **to support pharmacokinetics-pharmacodynamics (PK-PD) and efficacy studies**

LIFE SCIENCE
CHEMISTRY



DISCOVERY
BIOSCIENCES




IN VIVO
PHARMACOLOGY



DMPK





Hit Degradation Identification to *In Vivo* Proof-of-Concept



Life Science Chemistry

We offer innovative strategies for the rapid discovery of PROTACs and molecular glues across all business models, including consulting, degrader design, fast library synthesis, and integrated projects from conception to success.

- *In silico* tools supported PROTACs and Glues Design
- Ready-to-use collection of linkers and E3 binders
- Fast synthesis & Direct-to-Biology
- Multi-parameter optimization



Discovery Biosciences

Our platform encompasses all assay formats for cell-free and cell-based assays, covering target engagement, ternary complex formation, target degradation, and mode-of-action analysis.

- Biochemical: ASMS, SPR, TSA, X-Ray, HTRF and NanoBRET
- Cell-based: HCA, HiBiT (CRISPR KI or OE), NanoBRET, AlphaLISA, Western Blot, ProteinSimple
- Proteomics for selectivity of degradation
- Customer-specific assays / Assay development services



In Vivo Pharmacology

Integrated pharmacology services covering the entire drug discovery and development chain. We have various *in vivo* models available for different therapeutic areas to support:

- Efficacy studies
- Exposure studies
- Biomarker studies correlating PK-PD relationship
- Formulation approaches to ensure bioavailability of compounds



DMPK (Drug Metabolism and Pharmacokinetics)

Our DMPK discovery bioanalysis services can support the stages of drug discovery, from lead confirmation and lead optimization to preclinical studies. We offer a comprehensive range of services:


- Pharmacokinetic (PK) and pharmacodynamic (PD) analysis
- Toxicokinetic analysis
- High-quality PK/PD assessments with industry-standard PK/PD analysis tools

The Science CRO - From Target to Patient

The NUVISAN group is a contract research and development and manufacturing organization (CRO/CDMO) with six sites in Germany and France as well as local experts situated in Latin America.

We offer unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain to our biotech startup, pharma, non-profit, and venture capital clients – from target identification to the patient.

Thanks to more than 40 years of experience and about 1,000 employees (incl. > 70 % industry experienced scientists and lab professionals), we know how to discover, develop, and bring the next generation medicines to market. At the same time, our scientists understand that every project is different. With a flexible and innovative approach and transparent communication, our teams are passionate about closely collaborating with you to adapt to your individual needs.



Contact us



Dr. Katrin Jünemann
Lab Head at Therapeutic Compound Research
katrin.juenemann@nuvisan.com



Dr. Christoph Sachse
VP Business Development
christoph.sachse@nuvisan.com

NUVISAN ICB GmbH
Muellerstr. 178
13353 Berlin, Germany

Web: www.nuvisan.com
Email: hello@nuvisan.com
LinkedIn: [company/nuvisan](https://www.linkedin.com/company/nuvisan)